# CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

> **NCT07213206** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 1500 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** CDK 4/6 inhibitor combined therapy (omit chemo)
- **DRUG:** standard of care

## Key facts

- **NCT ID:** NCT07213206
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2032-09-01
- **Final completion:** 2035-09-01
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213206, "CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07213206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*